Coagulation modifiers

Overview
Coagulation modifiers are a broad group of agents that influence the clotting process by either inhibiting, promoting, or modifying blood coagulation pathways. They are used in the prevention and treatment of thromboembolic disorders, management of bleeding conditions, and in certain diagnostic and surgical contexts. These drugs act on different points of the hemostatic process, which includes platelet activation, the coagulation cascade, and fibrinolysis.

---

Major Categories and Mechanisms

1. Anticoagulants – Inhibit clot formation by interfering with the coagulation cascade

   • Vitamin K antagonists: Warfarin, Acenocoumarol, Phenprocoumon – inhibit vitamin K–dependent clotting factors (II, VII, IX, X) and proteins C and S.

   • Heparins: Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs, e.g., enoxaparin, dalteparin) – potentiate antithrombin III, inhibiting thrombin and factor Xa.

   • Direct oral anticoagulants (DOACs):

     • Direct thrombin inhibitor – Dabigatran

     • Direct factor Xa inhibitors – Rivaroxaban, Apixaban, Edoxaban, Betrixaban

   • Parenteral direct thrombin inhibitors: Argatroban, Bivalirudin, Lepirudin (discontinued in some markets)

   • Synthetic pentasaccharide: Fondaparinux – selectively inhibits factor Xa via antithrombin III.

2. Antiplatelet Agents – Inhibit platelet activation or aggregation

   • Cyclooxygenase (COX) inhibitors: Aspirin – irreversibly inhibits platelet COX-1, reducing thromboxane A₂.

   • P2Y₁₂ receptor inhibitors: Clopidogrel, Prasugrel, Ticagrelor, Cangrelor – block ADP-mediated platelet activation.

   • Glycoprotein IIb/IIIa inhibitors: Abciximab, Eptifibatide, Tirofiban – block fibrinogen binding to platelet GP IIb/IIIa receptor.

   • Phosphodiesterase inhibitors: Dipyridamole, Cilostazol – increase cAMP in platelets, reducing activation.

   • PAR-1 antagonist: Vorapaxar – inhibits thrombin-mediated platelet activation.

3. Thrombolytics (Fibrinolytics) – Promote clot breakdown by activating plasminogen to plasmin

   • Fibrin-specific: Alteplase, Reteplase, Tenecteplase – recombinant tissue plasminogen activators (tPAs).

   • Non-fibrin-specific: Streptokinase, Urokinase – act systemically on plasminogen.

4. Hemostatics (Procoagulants) – Promote clot formation

   • Systemic: Tranexamic acid, Aminocaproic acid – antifibrinolytics; Desmopressin – increases vWF and factor VIII release.

   • Factor concentrates:

     • Factor VIII, IX for hemophilia A or B

     • Prothrombin complex concentrate (PCC) – factors II, VII, IX, X

     • Fibrinogen concentrate

   • Topical hemostatic agents: Thrombin, fibrin sealants, collagen-based agents.

---

Therapeutic Uses

• Prevention and treatment of venous thromboembolism (VTE) and pulmonary embolism (PE)

• Stroke prevention in atrial fibrillation

• Secondary prevention after myocardial infarction

• Acute coronary syndromes (ACS) management

• Treatment of acute ischemic stroke or STEMI (thrombolytics)

• Control of surgical or traumatic bleeding

• Treatment of inherited coagulation disorders (hemophilia, von Willebrand disease)

---

Contraindications (general, vary by class)

• Active major bleeding

• Recent hemorrhagic stroke

• Severe uncontrolled hypertension (for many agents)

• Known hypersensitivity to the drug or its components

• Pregnancy (certain agents, e.g., warfarin)

---

Precautions

• Renal and hepatic impairment may require dose adjustments

• Monitor coagulation parameters (e.g., INR for warfarin, aPTT for UFH) where indicated

• Be aware of drug-drug interactions, especially with vitamin K antagonists and antiplatelet agents

• Weigh bleeding risk vs. thrombosis prevention need in each patient

---

Adverse Effects (class-dependent)

• Anticoagulants: Bleeding, bruising, heparin-induced thrombocytopenia (HIT with UFH/LMWH), gastrointestinal upset (warfarin).

• Antiplatelets: Bleeding, gastrointestinal irritation (aspirin), dyspnea (ticagrelor), rare thrombotic thrombocytopenic purpura (TTP) with clopidogrel.

• Thrombolytics: Major bleeding, intracranial hemorrhage, reperfusion arrhythmias, allergic reactions (streptokinase).

• Hemostatics: Thrombosis (with excessive use), hypotension (rapid infusion of antifibrinolytics), flushing (desmopressin).

---

Drug Interactions

• Additive bleeding risk with concurrent use of multiple anticoagulants or antiplatelets, NSAIDs, SSRIs/SNRIs.

• Warfarin: Numerous interactions (CYP2C9, CYP3A4 substrates/inhibitors/inducers, dietary vitamin K).

• DOACs: Interactions with strong P-gp and CYP3A4 inhibitors/inducers.

• Antifibrinolytics: Avoid use with thrombolytics unless reversing their effect.

Coagulation modifiers: comparative quick-reference

The table synthesizes core properties across the major classes—anticoagulants, antiplatelets, thrombolytics, and pro-coagulants—covering examples, mechanism, route, onset, monitoring, reversal, key adverse effects, and notable interactions. Dosing varies by indication and patient factors; use product labeling and local protocols for specifics.

Class	Representative drugs	Primary target and mechanism	Usual routes	Onset window	Routine monitoring	Reversal or mitigation	Key adverse effects	Important interactions	Practical pearls
Vitamin K antagonists (VKAs)	Warfarin, acenocoumarol, phenprocoumon	Inhibit VKORC1, reducing γ-carboxylation of factors II, VII, IX, X and proteins C/S	Oral	Delayed 24–72 h; full effect once existing factors clear	INR (target by indication); liver function if needed	Vitamin K (oral/IV), 4-factor PCC, FFP for major bleed	Bleeding, skin necrosis, purple toe, teratogenicity	Strong CYP2C9/CYP3A4 modulators, rifampicin, amiodarone, azoles, macrolides; variable dietary vitamin K; additive bleeding with antiplatelets/NSAIDs	Narrow therapeutic index; educate on diet, drug checks, and frequent INR during changes
Heparins (UFH, LMWH)	UFH; enoxaparin, dalteparin, tinzaparin	Potentiate antithrombin; UFH inhibits IIa and Xa, LMWH predominantly Xa	IV (UFH), SC (UFH/LMWH)	Immediate (IV UFH); LMWH within hours	aPTT for IV UFH; anti-Xa for LMWH in select scenarios	Protamine reverses UFH fully, LMWH partially	Bleeding, HIT (more with UFH), osteoporosis with long-term	Additive bleeding agents; caution with neuraxial anesthesia	UFH preferred with high bleeding risk or renal failure; LMWH predictable PK, outpatient friendly
Synthetic pentasaccharide	Fondaparinux	Selective factor Xa inhibition via antithrombin	SC	2–3 h	No routine lab; anti-Xa (calibrated) if needed	No specific antidote; PCCs may help in major bleed	Bleeding; rare HIT-like phenomena	Additive bleeding; avoid with neuraxial catheters	Contraindicated if severe renal impairment; long half-life simplifies once-daily dosing
Direct thrombin inhibitor (oral)	Dabigatran	Reversible direct IIa inhibitor	Oral	1–3 h	None routinely; thrombin time, dilute TT, ecarin clotting time if assessing	Idarucizumab	Bleeding, dyspepsia, GI upset; rare GI bleeding higher vs some Xa inhibitors	P-gp inhibitors/inducers; additive bleeding with antiplatelets/NSAIDs	Capsule must remain in original bottle/blister; renal dosing critical
Direct factor Xa inhibitors (DOACs)	Rivaroxaban, apixaban, edoxaban, betrixaban	Reversible direct Xa inhibition	Oral	1–4 h	None routinely; anti-Xa assays (drug-calibrated) if needed	Andexanet alfa for rivaroxaban/apixaban; PCCs off-label	Bleeding; rare hepatic enzyme rise	Strong CYP3A4/P-gp modulators; additive bleeding	Fixed dosing, fewer interactions than VKAs; adhere to renal/hepatic criteria
Parenteral DTIs	Bivalirudin, argatroban	Direct IIa inhibition independent of antithrombin	IV	Immediate	aPTT (or ACT in PCI)	No specific antidote; short half-life assists	Bleeding; argatroban elevates INR	Additive bleeding; hepatic metabolism for argatroban	Useful in HIT and PCI; choose by organ function (hepatic vs renal)
Antiplatelet: COX-1 inhibitor	Aspirin	Irreversible COX-1 inhibition → ↓TXA₂	Oral, rectal, IV	30–60 min	None routinely	Platelet transfusion in life-threatening bleed; DDAVP may help	GI irritation/ulcer, bleeding, bronchospasm in AERD	Additive bleeding; ibuprofen may blunt aspirin’s antiplatelet effect if timed improperly	Low-dose cardioprotection; take aspirin before ibuprofen or separate appropriately
Antiplatelet: P2Y12 inhibitors	Clopidogrel, prasugrel, ticagrelor, cangrelor (IV)	Block ADP P2Y12 receptor	Oral (C, P, T), IV (cangrelor)	Oral 2–6 h (loading faster); cangrelor immediate	Platelet function testing in select cases only	No antidotes; platelet transfusion post-washout; DDAVP sometimes used	Bleeding, dyspnea (ticagrelor), TTP rare (clopidogrel)	Strong CYP inhibitors/inducers; omeprazole can blunt clopidogrel activation	Choose agent by ACS strategy and bleeding risk; stop windows before surgery differ by agent
Antiplatelet: GP IIb/IIIa inhibitors	Abciximab, eptifibatide, tirofiban	Block final common pathway of platelet aggregation	IV	Immediate	Platelets if bleeding; monitor for thrombocytopenia	Stop infusion; platelet transfusion for abciximab-related bleeding	Bleeding, thrombocytopenia	Anticoagulants, fibrinolytics elevate bleeding risk	Reserved for PCI bail-out or select high-thrombus cases
Antiplatelet: PDE inhibitors	Dipyridamole, cilostazol	↑Platelet cAMP → ↓activation; vasodilation	Oral; dipyridamole also IV stress	Hours	None routinely	Supportive	Headache, flushing; cilostazol can cause palpitations	CYP3A4/CYP2C19 interactions (cilostazol)	Dipyridamole used with aspirin in secondary stroke prevention; cilostazol for intermittent claudication where tolerated
Antiplatelet: PAR-1 antagonist	Vorapaxar	Blocks thrombin receptor on platelets	Oral	Days to steady state	None routinely	No specific antidote	Bleeding, including intracranial	Additive bleeding with other antiplatelets/anticoagulants	Contraindicated with prior stroke/TIA or ICH
Thrombolytics (fibrinolytics)	Alteplase, tenecteplase, reteplase; streptokinase/urokinase	Convert plasminogen to plasmin → fibrin degradation	IV	Minutes	Fibrinogen, plasminogen, aPTT/PT in some protocols; clinical monitoring	Stop drug; cryoprecipitate, TXA/aminocaproic acid, platelets, PCC/FFP as per protocol	Major bleeding, ICH, hypotension; allergy with streptokinase	Recent surgery, severe HTN, prior ICH contraindicate use	Strict inclusion/exclusion criteria in AIS/STEMI/PE; stroke dosing time-critical
Antifibrinolytics	Tranexamic acid, aminocaproic acid	Lysine analogs block plasminogen activation and plasmin binding to fibrin	IV, oral, topical	Minutes to hours	None routinely	Not applicable; these are reversal adjuncts for hyperfibrinolysis	Thrombosis risk if overused, seizures (high-dose TXA), hypotension if rapid IV push	Caution with active DIC unless hemostasis secured	Use in trauma, PPH, surgical bleeding, heavy menses; adhere to timing windows
Desmopressin (DDAVP)	Desmopressin	Releases vWF and factor VIII from endothelium	IV, SC, intranasal	30–60 min	Sodium (hyponatremia risk)	Fluid restriction if needed	Hyponatremia, flushing, headache	SSRIs, carbamazepine may worsen hyponatremia	Useful in uremic platelet dysfunction, mild hemophilia A, type 1 vWD, and for antiplatelet-associated bleeding adjunct
Coagulation factor concentrates	rFVIIa, FVIII, FIX, FXI, fibrinogen concentrate, PCCs	Replace deficient clotting factor(s) or provide non-activated/activated complexes	IV	Immediate	Factor activity levels where appropriate	Specific to product; PCCs reverse VKAs; rFVIIa off-label rescue	Thrombosis, DIC risk if overcorrected	Concomitant anticoagulants/antiplatelets raise bleed risk	Match product to defect or reversal need; PCCs are preferred to FFP for rapid warfarin reversal
Topical hemostats and sealants	Thrombin, fibrin sealants, oxidized cellulose, collagen sponges	Local clot promotion and fibrin formation	Topical	Immediate	None	Not applicable systemically	Local reactions; theoretical infection risk	Interfere with re-operation planes	Adjuncts in surgery and trauma; do not substitute for systemic correction when needed

Cross-cutting clinical notes

Eligibility and selection
• Balance thrombotic risk, bleeding risk, organ function, drug interactions, and care setting
• In renal impairment, prefer UFH over LMWH/DOACs; adjust dabigatran and Xa inhibitors carefully
• In pregnancy, avoid warfarin; prefer LMWH for treatment and prophylaxis
• In mechanical valves, warfarin remains standard; DOACs are not indicated
• In HIT, stop all heparins and use non-heparin anticoagulants such as argatroban or bivalirudin

Peri-procedural management
• For VKAs, individualize stop time to target INR; use PCC plus vitamin K for urgent reversal
• For DOACs, hold based on renal function and bleeding risk of the procedure; specific reversal where available for life-threatening bleed
• Coordinate timing with neuraxial anesthesia to avoid spinal hematoma with heparins and DOACs

Laboratory interpretation tips
• Prolonged thrombin time suggests dabigatran effect; anti-Xa assays calibrated to drug can quantify Xa inhibitors; INR is unreliable for DOACs
• D-dimer rise after thrombolysis is expected; falling fibrinogen may signal systemic fibrinolysis requiring cryoprecipitate

Bleeding management framework
• Identify agent and last dose; apply local measures and supportive care first
• Use targeted antidotes when available; otherwise escalate with PCCs, cryoprecipitate, platelets, and antifibrinolytics per protocol
• Reassess indication and restart anticoagulation when safe to reduce thrombosis rebound